Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.53 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.53 |
| ▸ | CAMKK2 | Q96RR4 | 3/20 | 0.46 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.45 |
| ▸ | AXL | P30530 | 3/20 | 0.45 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.45 |
| ▸ | CDK8 | P49336 | 1/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.45 |
| ▸ | SGK1 | O00141 | 4/20 | 0.44 |
| ▸ | KIT | P10721 | 3/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.42 |
| ▸ | CLK1 | P49759 | 1/20 | 0.42 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.42 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8320356 | 0.92 | MAPK8 (0.52) | MAPK8MAPK9MAPK10CAMKK2MAP3K11 | |
| SCHEMBL8321704 | 0.89 | MAPK8 (0.55) | MAPK8MAPK9MAPK10CAMKK2MAP3K11 | |
| SCHEMBL8319995 | 0.89 | MAPK8 (0.49) | MAPK8MAPK9MAPK10CAMKK2MAP3K11 | |
| SCHEMBL12829887 | 0.88 | MAPK8 (0.48) | MAPK8MAPK9MAPK10CAMKK2MAP3K11 | |
| SCHEMBL8320310 | 0.86 | MAPK8 (0.60) | MAPK8MAPK9MAPK10CAMKK2MAP3K11 | |
| SCHEMBL13745419 | 0.84 | MAPK8 (0.54) | MAPK8MAPK9MAPK10CAMKK2MAP3K11 | |
| SCHEMBL8321137 | 0.84 | MAPK8 (0.52) | MAPK8MAPK9MAPK10CAMKK2MAP3K11 | |
| SCHEMBL8317033 | 0.84 | MAPK8 (0.58) | MAPK8MAPK9MAPK10CAMKK2MAP3K11 | |
| SCHEMBL8320207 | 0.83 | MAPK8 (0.52) | MAPK8MAPK9MAPK10CAMKK2MAP3K11 | |
| SCHEMBL12829886 | 0.82 | MAPK8 (0.56) | MAPK8MAPK9MAPK10CAMKK2MAP3K11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295433-A2 | JNK inhibitors | Eisai R&D Management Co., Ltd. (JP) | 2011-03-16 | — | — | EP | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| WO-2004078756-A2 | JNK INHIBITORS | EISAI CO., LTD. (JP) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | MAPK8 50/4885MAPK9 43/4885MAPK10 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.